J&J's (JNJ +0.2%) and Bayer's (BAYRY.PK) Xarelto blood thinner significantly cut...

|By:, SA News Editor

J&J's (JNJ +0.2%) and Bayer's (BAYRY.PK) Xarelto blood thinner significantly cut cardiovascular death, heart attacks and strokes in patients who have suffered a severe heart attack and when used with with standard treatments. The results came from  a Phase III trial that was testing Xarelto for use in acute coronary syndrome, for which the companies are trying to receive FDA approval after a rejection in June. (PR)